Arrowhead Pharmaceuticals, Inc. (ARWR) — Analyst outlook / Analyst consensus target is. Based on 20 analyst ratings, the consensus is bullish — 14 Buy, 6 Hold.
The consensus price target is $78.78 (low: $35.00, high: $110.00), representing an upside of 18.1% from the current price $66.69.
Analysts estimate Earnings Per Share (EPS) of $-4.70 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.00 vs est $-4.70 (missed -6.4%). 2025: actual $-0.01 vs est $0.09 (missed -113.8%). Analyst accuracy: 0%.
ARWR Stock — 12-Month Price Forecast
$78.78
▲ +18.13% Upside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for Arrowhead Pharmaceuticals, Inc., the average price target is $78.78, with a high forecast of $110.00, and a low forecast of $35.00.
The average price target represents a +18.13% change from the last price of $66.69.
Highest Price Target
$110.00
Average Price Target
$78.78
Lowest Price Target
$35.00
ARWR Analyst Ratings
Buy
Based on 20 analysts giving stock ratings to Arrowhead Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ARWR
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$5.00
vs Est –$4.70
▼ 6.1% off
2025
Actual –$0.01
vs Est $0.09
▼ 824.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ARWR
55%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.355B
vs Est $0.062B
▲ 82.5% off
2025
Actual $0.829B
vs Est $0.765B
▲ 7.8% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
